Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Betamethasone
Drug ID BADD_D00260
Description Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties.[A192444] It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders.[A192444] Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.[A192444]
Indications and Usage As a member of the corticosteroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As topical monotherapy, betamethasone is indicated to relieve pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses.[L11991,L10782,L11997] Betamethasone can be used topically in combination with a vitamin D analog such as calcipotriene to treat plaque psoriasis.[L12000] The corticosteroid is also available as an injectable suspension and can be used to manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions.[L11994]
Marketing Status approved; vet_approved
ATC Code A07EA04; C05AA05; D07AC01; D07XC01; H02AB01; R01AD06; R03BA04; S01BA06; S01CB04; S02BA07; S03BA03
DrugBank ID DB00443
KEGG ID D00244
MeSH ID D001623
PubChem ID 9782
TTD Drug ID D0CW1P
NDC Product Code 52128-166; 22552-0030; 57582-007; 64958-0012
UNII 9842X06Q6M
Synonyms Betamethasone | Flubenisolone | Betadexamethasone | Celestona | Cellestoderm | Celeston | Celestone
Chemical Information
Molecular Formula C22H29FO5
CAS Registry Number 378-44-9
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Immunodeficiency10.03.02.002--Not Available
Psychotic disorder19.03.01.002--
Hyperlipidaemia14.08.03.001--
Increased upper airway secretion22.12.03.007--Not Available
Chorioretinopathy06.09.01.0060.000127%Not Available
Skin haemorrhage24.07.01.103; 23.06.07.001--Not Available
Joint instability15.01.08.007--Not Available
Treatment failure08.06.01.017--Not Available
Low birth weight baby18.04.02.003--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Bladder dysfunction20.03.03.002--Not Available
Sperm concentration abnormal13.20.04.007--Not Available
Neonatal respiratory distress syndrome18.04.10.003; 22.11.02.010--Not Available
Skin plaque23.03.03.044--Not Available
Catheter site irritation12.07.02.022; 08.02.02.022--Not Available
Central serous chorioretinopathy06.10.02.009--Not Available
Gait inability08.01.02.011; 17.02.05.069--Not Available
Idiopathic intracranial hypertension17.07.02.011--Not Available
Illness08.01.03.091--Not Available
Injection site hypoaesthesia08.02.03.060; 17.02.06.051; 12.07.03.060--Not Available
Palmoplantar pustulosis23.03.14.011; 10.02.01.099--Not Available
Therapeutic product effect decreased08.06.01.050--Not Available
Therapeutic product effect incomplete08.06.01.052--Not Available
Therapeutic product ineffective08.06.01.057--Not Available
Therapeutic response shortened08.06.01.062--Not Available
Therapy non-responder08.06.01.063--Not Available
Therapy partial responder08.06.01.064--Not Available
The 9th Page    First    Pre   9    Total 9 Pages